Inventiva S.A. (NASDAQ:IVA - Get Free Report)'s stock price was down 0.7% during trading on Friday . The company traded as low as $2.74 and last traded at $2.98. Approximately 6,833 shares traded hands during trading, a decline of 90% from the average daily volume of 66,689 shares. The stock had previously closed at $3.00.
Analyst Upgrades and Downgrades
A number of equities research analysts have recently commented on IVA shares. HC Wainwright reiterated a "buy" rating and set a $13.00 price target on shares of Inventiva in a report on Thursday, January 30th. TD Cowen started coverage on shares of Inventiva in a report on Friday, February 21st. They issued a "buy" rating and a $10.00 target price on the stock. Finally, Stifel Nicolaus dropped their target price on shares of Inventiva from $20.00 to $17.00 and set a "buy" rating on the stock in a report on Friday, November 22nd. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $12.60.
View Our Latest Report on Inventiva
Inventiva Price Performance
The company's fifty day moving average is $2.58 and its 200-day moving average is $2.45.
About Inventiva
(
Get Free Report)
Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.
Featured Stories
Before you consider Inventiva, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inventiva wasn't on the list.
While Inventiva currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
